What is the address of NEFROZOL?

The registered office of NEFROZOL is located at Schutenseweg 22 box a, 3520 Zonhoven.

Is NEFROZOL still active?

Yes. According to the CBE (31 October 2026) NEFROZOL is active, legal situation “Normale toestand”, started on 23 May 2018.

Is NEFROZOL registered on Peppol?

No, NEFROZOL is currently not registered on the Peppol network.

What is the enterprise number of NEFROZOL?

The enterprise number of NEFROZOL is BE0696722789.

When was NEFROZOL founded?

NEFROZOL was founded on 23 May 2018.

Is NEFROZOL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 May 2018; 5 annual accounts filed, latest fiscal year 2025; 7 directors known from the annual account.

How much profit did NEFROZOL make in 2025?

NEFROZOL posted a profit after taxes of € 5,160 in financial year 2025.

What is the revenue of NEFROZOL?

As a small company, NEFROZOL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 6,955.

NEFROZOL (Private Limited) - Zonhoven - BE0696722789

Q: Who are the directors of NEFROZOL?

According to the 2025 annual accounts, the directors of NEFROZOL are: MEDISCH KABINET DR. L. HENDRICKX BV, DOKTER BEN SPRANGERS BV, DR. E. MACKEN BV, DOKTER JACQUES PEETERS BV, DR. CHRISTOPH METALIDIS BV, DR. VAN MIEGHEM ANN BV, NEFRON BV.

Dossier NEFROZOL, printed on 31 October 2026 from databakkes.be/en/0696722789/nefrozol. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

NEFROZOL from Zonhoven, company number BE0696722789, closed financial year 2025 with a result of € 5,160 after tax. For that financial year NEFROZOL recorded a gross margin of € 6,955 and equity of € 14,334. Compared with financial year 2024, the result moved from € -3,253 to € 5,160. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 14,334

▲ 56% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 5,160

▲ still € 3,253 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 66,786

▲ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -7,366.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2.1 million

▲ 7% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -10,648 Gross margin 2022: € -10,648 First fiscal year in the series	€ 5,554 Gross margin 2023: € 5,554 ▲ € 16,202 vs 2022 (€ -10,648) Favourable step	€ -1,492 Gross margin 2024: € -1,492 ▼ € 7,046 vs 2023 (€ 5,554) Unfavourable step	€ 6,955 Gross margin 2025: € 6,955 ▲ € 8,447 vs 2024 (€ -1,492) Favourable step	▲ € 8,447
Profit after taxes	€ -13,369 Profit after taxes 2022: € -13,369 First fiscal year in the series	€ 3,737 Profit after taxes 2023: € 3,737 ▲ € 17,106 vs 2022 (€ -13,369) Favourable step	€ -3,253 Profit after taxes 2024: € -3,253 ▼ € 6,990 vs 2023 (€ 3,737) Unfavourable step	€ 5,160 Profit after taxes 2025: € 5,160 ▲ € 8,413 vs 2024 (€ -3,253) Favourable step	▲ € 8,413
Equity	€ 5,590 Equity 2022: € 5,590 First fiscal year in the series	€ 12,427 Equity 2023: € 12,427 ▲ 122% vs 2022 (€ 5,590) Favourable step	€ 9,174 Equity 2024: € 9,174 ▼ 26% vs 2023 (€ 12,427) Unfavourable step	€ 14,334 Equity 2025: € 14,334 ▲ 56% vs 2024 (€ 9,174) Favourable step	▲ 56%
Total debts	€ 1,669,317 Total debts 2022: € 1,669,317 First fiscal year in the series	€ 1,904,079 Total debts 2023: € 1,904,079 ▲ 14% vs 2022 (€ 1,669,317) Unfavourable step	€ 1,942,908 Total debts 2024: € 1,942,908 ▲ 2% vs 2023 (€ 1,904,079) Unfavourable step	€ 2,088,017 Total debts 2025: € 2,088,017 ▲ 7% vs 2024 (€ 1,942,908) Unfavourable step	▲ 7%
Cash	€ 39,804 Cash 2022: € 39,804 First fiscal year in the series	€ 46,123 Cash 2023: € 46,123 ▲ 16% vs 2022 (€ 39,804) Favourable step	€ 63,715 Cash 2024: € 63,715 ▲ 38% vs 2023 (€ 46,123) Favourable step	€ 66,786 Cash 2025: € 66,786 ▲ 5% vs 2024 (€ 63,715) Favourable step	▲ 5%
Retained profit	€ -13,010 Retained profit 2022: € -13,010 First fiscal year in the series	€ -9,273 Retained profit 2023: € -9,273 ▲ € 3,737 vs 2022 (€ -13,010) Favourable step	€ -12,526 Retained profit 2024: € -12,526 ▼ € 3,253 vs 2023 (€ -9,273) Unfavourable step	€ -7,366 Retained profit 2025: € -7,366 ▲ € 5,160 vs 2024 (€ -12,526) Favourable step	▲ € 5,160
Balance sheet total	€ 1,674,907 Balance sheet total 2022: € 1,674,907 First fiscal year in the series	€ 1,916,506 Balance sheet total 2023: € 1,916,506 ▲ 14% vs 2022 (€ 1,674,907) Unchanged	€ 1,952,083 Balance sheet total 2024: € 1,952,083 ▲ 2% vs 2023 (€ 1,916,506) Unchanged	€ 2,102,351 Balance sheet total 2025: € 2,102,351 ▲ 8% vs 2024 (€ 1,952,083) Unchanged	▲ 8%

Key figures of NEFROZOL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to NEFROZOL?

What happened at NEFROZOL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 5,160. filed late Source: NBB ↗
2023 DOKTER BEN SPRANGERS BV became a director. NBB
2022 NEFRON BV became a director. NBB
May 23, 2018 New establishment in Genk. KBO
2018 MEDISCH KABINET DR. L. HENDRICKX BV became a director. NBB
2018 DR. E. MACKEN BV became a director. NBB
2018 DOKTER JACQUES PEETERS BV became a director. NBB
2018 DR. CHRISTOPH METALIDIS BV became a director. NBB

In short

From € 13,369 loss in 2022 to € 5,160 profit in 2025.

Paid € 1,707 in corporate taxes since 2022.

Best year ever: 2025, with € 5,160 profit.

Original PDFs at the National Bank ↗

Management

Dr. Christoph Metalidis 16.7%

Dr. E. Macken 16.7%

DR. VAN MIEGHEM ANN 14.3%

The stake of Dr. Christoph Metalidis, Dr. E. Macken, DR. VAN MIEGHEM ANN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

NEFROZOL

Behind NEFROZOL are MEDISCH KABINET DR. L. HENDRICKX BV, DOKTER BEN SPRANGERS BV, DR. E. MACKEN BV, DOKTER JACQUES PEETERS BV, DR. CHRISTOPH METALIDIS BV and DR. VAN MIEGHEM ANN BV. The shares are held by Dr. Christoph Metalidis (16.7%), Dr. E. Macken (16.7%) and DR. VAN MIEGHEM ANN (14.3%).